MiR-30a-5p frequently downregulated in prostate cancer inhibits cell proliferation via targeting PCLAF

Reference

• Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. CA: a Cancer Journal for Clinicians. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Rebbeck TR. Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol. 2017;27:3–10.
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–2035.
   PubMed Web of Science ®Google Scholar
• Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015;68:464–470.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang HK, Qu YY, et al. Prostate cancer in East Asia: evolving trend over the last decade. Asian J Androl. 2015;17:48–57.
   PubMed Web of Science ®Google Scholar
• Vidigal JA, Ventura A. The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol. 2015;25:137–147.
   PubMed Web of Science ®Google Scholar
• Hu Y, Lan W, Miller D. Next-generation sequencing for MicroRNA expression profile. Methods Mol Biol. 2017;1617:169–177.
   PubMedGoogle Scholar
• Song C, Chen H, Wang T, et al. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing. Prostate. 2015;75:500.
   PubMed Web of Science ®Google Scholar
• Yang SJ, Yang SY, Wang DD, et al. The miR-30 family: versatile players in breast cancer. Tumour Biol. 2017;39:1010428317692204.
   Google Scholar
• Liu MM, Li Z, Han XD, et al. MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in Breast Cancer. Sci Rep. 2017;7:15929.
   PubMed Web of Science ®Google Scholar
• Kao CJ, Martiniez A, Shi XB, et al. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 2014;33:2495–2503.
   PubMed Web of Science ®Google Scholar
• Egan SM, Karasik E, Ellis L, et al. miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth. Oncotarget. 2017;8:67626–67638.
   PubMedGoogle Scholar
• Zhao H, Bian H, Bu X, et al. Targeting of Discoidin Domain Receptor 2 (DDR2) prevents myofibroblast activation and neovessel formation during pulmonary fibrosis. Mol Ther. 2016;24:1734–1744.
   PubMed Web of Science ®Google Scholar
• Broad Institute TCGA Genome Data Analysis Center. Identification of Putative miR Direct Targets by Sequencing Data. Broad Institute of MIT and Harvard; 2016. doi:10.7908/C10R9NV4.
   Google Scholar
• Yang Z, Wu L, Wang A, et al. dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers. Nucleic Acids Res. 2017;45:D812–D818.
   PubMed Web of Science ®Google Scholar
• Vlachos IS, Zagganas K, Paraskevopoulou MD, et al. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 2015;43:W460–W466.
   PubMed Web of Science ®Google Scholar
• Ludwig N, Leidinger P, Becker K, et al. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016;44:3865–3877.
   PubMed Web of Science ®Google Scholar
• Hsu SD, Chu CH, Tsou AP, et al. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res. 2008;36:D165–D169.
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46:D956–D963.
   PubMed Web of Science ®Google Scholar
• Chou CH, Shrestha S, Yang CD, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46:D296–D302.
   PubMed Web of Science ®Google Scholar
• Agarwal V, Bell GW, Nam JW , et al. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015;4:e05005.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649–658.
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–607.
   PubMed Web of Science ®Google Scholar
• Backes C, Fehlmann T, Kern F, et al. miRCarta: a central repository for collecting miRNA candidates. Nucleic Acids Res. 2018;46:D160–D167.
   PubMed Web of Science ®Google Scholar
• Ouzounova M, Vuong T, Ancey PB, et al. MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells. BMC Genomics. 2013;14:139.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Lin J, Zhu D, et al. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res. 2014;74:1801–1813.
   PubMed Web of Science ®Google Scholar
• Fan MJ, Zhong YH, Shen W, et al. MiR-30 suppresses lung cancer cell 95D epithelial mesenchymal transition and invasion through targeted regulating Snail. Eur Rev Med Pharma Sci. 2017;21:2642–2649.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Xia Y, Wang P, et al. Low expression of microRNA-30c promotes invasion by inducing epithelial mesenchymal transition in non-small cell lung cancer. Mol Med Rep. 2014;10:2575–2579.
   PubMed Web of Science ®Google Scholar
• Xu CG, Yang MF, Fan JX, et al. MiR-30a and miR-205 are downregulated in hypoxia and modulate radiosensitivity of prostate cancer cells by inhibiting autophagy via TP53INP1. Eur Rev Med Pharma Sci. 2016;20:1501–1508.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Uemura H, Nagahama K, et al. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget. 2012;3:1455–1471.
   PubMedGoogle Scholar
• Kumar B, Khaleghzadegan S, Mears B, et al. Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. Oncotarget. 2016;7:72593–72607.
   PubMedGoogle Scholar
• Zhong B, Guo S, Zhang W, et al. Bioinformatics prediction of miR-30a targets and its inhibition of cell proliferation of osteosarcoma by up-regulating the expression of PTEN. BMC Med Genomics. 2017;10:64.
   PubMed Web of Science ®Google Scholar
• Wang M, Xie R, Si H, et al. Integrated bioinformatics analysis of miRNA expression in osteosarcoma. Artif Cells Nanomed Biotechnol. 2017;45:936–943.
   PubMed Web of Science ®Google Scholar
• Zhu K, Diao D, Dang C, et al. Elevated KIAA0101 expression is a marker of recurrence in human gastric cancer. Cancer Sci. 2013;104:353–359.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Li K, Diao D, et al. Expression of KIAA0101 protein is associated with poor survival of esophageal cancer patients and resistance to cisplatin treatment in vitro. Lab Invest. 2013;93:1276–1287.
   PubMed Web of Science ®Google Scholar
• Jain M, Zhang L, Patterson EE, et al. KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. PloS One. 2011;6:e26866.
   PubMed Web of Science ®Google Scholar
• Su X, Zhang T, Cheng P, et al. KIAA0101 mRNA overexpression in peripheral blood mononuclear cells acts as predictive marker for hepatic cancer. Tumor Biol. 2014;35:2681–2686.
   PubMedGoogle Scholar
• Hosokawa M, Takehara A, Matsuda K, et al. Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. Cancer Res. 2007;67:2568–2576.
   PubMed Web of Science ®Google Scholar
• Kato T, Daigo Y, Aragaki M, et al. Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients. Lung Cancer. 2012;75:110–118.
   PubMed Web of Science ®Google Scholar
• Shaw GL, Whitaker H, Corcoran M, et al. The early effects of rapid androgen deprivation on human prostate cancer. Eur Urol. 2016;70:214–218.
   PubMed Web of Science ®Google Scholar